{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:46Z","timestamp":1787002666418,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41409-025-02760-6","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:20:53Z","timestamp":1764948053000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of eltrombopag for treatment of thrombocytopenia in the setting of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3326-2141","authenticated-orcid":false,"given":"Arni","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arin","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2029-6753","authenticated-orcid":false,"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-5440","authenticated-orcid":false,"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-8233","authenticated-orcid":false,"given":"Razan","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-4248","authenticated-orcid":false,"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-4620","authenticated-orcid":false,"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2760_CR1","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/bmt.2013.35","volume":"48","author":"M Ayas","year":"2013","unstructured":"Ayas M, Nassar A, Hamidieh AA, Kharfan-Dabaja M, Othman TB, Elhaddad A, et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transpl. 2013;48:1168\u201372. https:\/\/doi.org\/10.1038\/bmt.2013.35.","journal-title":"Bone Marrow Transpl"},{"key":"2760_CR2","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa1004383.","journal-title":"N Engl J Med"},{"key":"2760_CR3","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1056\/NEJM199804023381405","volume":"338","author":"JA Hansen","year":"1998","unstructured":"Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962\u20138. https:\/\/doi.org\/10.1056\/NEJM199804023381405.","journal-title":"N Engl J Med"},{"key":"2760_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2400192","DOI":"10.1056\/EVIDoa2400192","volume":"4","author":"AA Kassim","year":"2025","unstructured":"Kassim AA, Walters MC, Eapen M, Smith M, Logan BR, Solh M, et al. Haploidentical bone marrow transplantation for sickle cell disease. NEJM Evid. 2025;4:EVIDoa2400192 https:\/\/doi.org\/10.1056\/EVIDoa2400192.","journal-title":"NEJM Evid"},{"key":"2760_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.14954","volume":"179","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017;179:781\u20139. https:\/\/doi.org\/10.1111\/bjh.14954.","journal-title":"Br J Haematol"},{"key":"2760_CR6","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kroger","year":"2024","unstructured":"Kroger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11:e62\u2013e74. https:\/\/doi.org\/10.1016\/S2352-3026(23)00305-8.","journal-title":"Lancet Haematol"},{"key":"2760_CR7","doi-asserted-by":"publisher","unstructured":"Bento L, Canaro M, Bastida JM, Sampol A. Thrombocytopenia and therapeutic strategies after allogeneic hematopoietic stem cell transplantation. J Clin Med. 2022;11; https:\/\/doi.org\/10.3390\/jcm11051364","DOI":"10.3390\/jcm11051364"},{"key":"2760_CR8","unstructured":"ASHP. Eltrombopag. In: Bethesda. Maryland: The American Society of Health-System Pharmacists; 2004."},{"key":"2760_CR9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71 https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2760_CR10","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa, Ontario: University of Ottawa."},{"key":"2760_CR11","unstructured":"STATA, 18.5 ed. College Station, TX: StataCorp LLC; 2023."},{"key":"2760_CR12","unstructured":"Deeks JJHJ, Altman DG, McKenzie JE and Veroniki AA. Chapter 10: Analysing data and undertaking meta-analyses. In: Julian Higgins JT, editor, Cochrane Handbook for Systematic Reviews of Interventions, version 6.5. Cochrane: Chichester (UK): 2024."},{"key":"2760_CR13","doi-asserted-by":"publisher","first-page":"430 e431","DOI":"10.1016\/j.jtct.2021.02.004","volume":"27","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, et al. Eltrombopag for post-transplantation thrombocytopenia: results of phase II randomized, double-blind, placebo-controlled trial. Transplant Cell Ther. 2021;27:430 e431\u2013430 e437. https:\/\/doi.org\/10.1016\/j.jtct.2021.02.004.","journal-title":"Transplant Cell Ther"},{"key":"2760_CR14","unstructured":"Aguirre L, Lizardi A, Bachiller P, Esteban B, Gonzalez C, Argoitia N, et al. Eltrombopag (EPAG) induces a high percentage of responses in patients with post allo-HSCT poor graft function (PGF) and no active GVHD. Bone Marrow Transplantation 2019;54(supplement 1):228\u2013229."},{"key":"2760_CR15","doi-asserted-by":"publisher","first-page":"e44555","DOI":"10.7759\/cureus.44555","volume":"15","author":"E Arslan Davulcu","year":"2023","unstructured":"Arslan Davulcu E, Akad Soyer N, Vural F. Eltrombopag for the treatment of allogeneic hematopoietic stem cell transplantation-related poor graft function. Cureus. 2023;15:e44555 https:\/\/doi.org\/10.7759\/cureus.44555.","journal-title":"Cureus"},{"key":"2760_CR16","doi-asserted-by":"crossref","unstructured":"Bostankolu De\u011firmenci B, Yegin ZA, Dikyar A, Ayd\u0131n Kaynar L, \u00d6zkurt ZN, Uyar G\u00f6\u00e7\u00fcn P et al. Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia. Leuk Res. 2022:118:106870.","DOI":"10.1016\/j.leukres.2022.106870"},{"key":"2760_CR17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41409-019-0435-2","volume":"54","author":"H Fu","year":"2019","unstructured":"Fu H, Zhang X, Han T, Mo X, Wang Y, Chen H, et al. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54:1310\u20138. https:\/\/doi.org\/10.1038\/s41409-019-0435-2.","journal-title":"Bone Marrow Transplant"},{"key":"2760_CR18","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s00277-020-04106-2","volume":"99","author":"F Gao","year":"2020","unstructured":"Gao F, Zhou X, Shi J, Luo Y, Tan Y, Fu H, et al. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia. Ann Hematol. 2020;99:2679\u201387. https:\/\/doi.org\/10.1007\/s00277-020-04106-2.","journal-title":"Ann Hematol"},{"key":"2760_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4274\/tjh.galenos.2022.2021.0675","volume":"39","author":"ZT Guven","year":"2022","unstructured":"Guven ZT, Celik S, Eser B, Cetin M, Unal A, Kaynar L. Eltrombopag for treatment of thrombocytopenia following hematopoietic stem cell transplantation. Turk J Haematol. 2022;39:103\u20138. https:\/\/doi.org\/10.4274\/tjh.galenos.2022.2021.0675.","journal-title":"Turk J Haematol"},{"key":"2760_CR20","doi-asserted-by":"crossref","unstructured":"He G, Karrison T, Stock W, Larson RA, Kosuri S, LaBelle JL, et al. Eltrombopag is a safe and effective agent to treat thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In: 2023 Tandem Meetings. Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Tandem Meetings. 2023;29:S142\u2013S143.","DOI":"10.1016\/S2666-6367(23)00247-6"},{"key":"2760_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.55730\/1300-0144.5328","volume":"52","author":"A Karatas","year":"2022","unstructured":"Karatas A, Goker H, Demiroglu H, Malkan UY, Velet M, Cinar OE, et al. Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation. Turk J Med Sci. 2022;52:413\u20139. https:\/\/doi.org\/10.55730\/1300-0144.5328.","journal-title":"Turk J Med Sci"},{"key":"2760_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107484","volume":"140","author":"E Kilic Gunes","year":"2024","unstructured":"Kilic Gunes E, Yigit Kaya S, Yaman F, Yeniay MK, Vural K, Comert M, et al. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: a multicenter real-world experience. Leuk Res. 2024;140:107484. https:\/\/doi.org\/10.1016\/j.leukres.2024.107484.","journal-title":"Leuk Res"},{"key":"2760_CR23","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1038\/s41409-021-01362-2","volume":"56","author":"RV Nampoothiri","year":"2021","unstructured":"Nampoothiri RV, Ho L, McEwan C, Pasic I, Lam W, Law AD, et al. Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2021;56:2471\u20136. https:\/\/doi.org\/10.1038\/s41409-021-01362-2.","journal-title":"Bone Marrow Transpl"},{"key":"2760_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41409-018-0368-1","volume":"54","author":"D Rivera","year":"2019","unstructured":"Rivera D, Bastida JM, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A, et al. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transpl. 2019;54:757\u201361. https:\/\/doi.org\/10.1038\/s41409-018-0368-1.","journal-title":"Bone Marrow Transpl"},{"key":"2760_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bbmt.2016.01.018","volume":"22","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22:919\u201324. https:\/\/doi.org\/10.1016\/j.bbmt.2016.01.018.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2760_CR26","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1016\/j.bbmt.2019.12.376","volume":"26","author":"TP Wang","year":"2020","unstructured":"Wang TP, Lin RY, Pereira D, Beitinjaneh A, Lekakis LJ, Jimenez AM, et al. Eltrombopag may improve platelet recovery in the outpatient setting after allogeneic stem cell transplant. Biology Blood Marrow Transplant. 2020;26:S343.","journal-title":"Biology Blood Marrow Transplant"},{"key":"2760_CR27","doi-asserted-by":"crossref","unstructured":"Yan F, Lu N, Gu Z, Huang W, Wang S, Gao X et al. Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience. Ann Hematol. 2022;101:397\u2013408.","DOI":"10.1007\/s00277-021-04706-6"},{"key":"2760_CR28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.bbmt.2019.01.027","volume":"25","author":"C Yuan","year":"2019","unstructured":"Yuan C, Boyd AM, Nelson J, Patel RD, Varela JC, Goldstein SC, et al. Eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:1320\u20134. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.027.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2760_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/01.Hs9.0000846232.58961.88","volume":"6","author":"C Vallejo","year":"2022","unstructured":"Vallejo C, Garc\u00eda I, Sanchez Guijo F, Cuesta M, Solano C, Sampol A, et al. P837: Eltrombopag (epag) induces hematologic responses for patients with post-allogenic hematopoietic stem cell transplant poor graft function (post-allo hsct pgf): results of the eltion study in spain. HemaSphere. 2022;6:731\u20132. https:\/\/doi.org\/10.1097\/01.Hs9.0000846232.58961.88.","journal-title":"HemaSphere"},{"key":"2760_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2147\/ITT.S463384","volume":"13","author":"A Elsayed","year":"2024","unstructured":"Elsayed A, Elsayed B, Elmarasi M, Elsabagh AA, Elsayed E, Elmakaty I, et al. Thrombopoietin receptor agonists in post-hematopoietic cell transplantation complicated by prolonged thrombocytopenia: a comprehensive review. Immunotargets Ther. 2024;13:461\u201386. https:\/\/doi.org\/10.2147\/ITT.S463384.","journal-title":"Immunotargets Ther"},{"key":"2760_CR31","volume-title":"PROMACTA (eltrombopag)[package insert","author":"AG Novartis","year":"2008","unstructured":"Novartis AG PROMACTA (eltrombopag)[package insert. U.S. Food and Drug Administration website; 2008."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02760-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:02:59Z","timestamp":1771282979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02760-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2760"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02760-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AK, AS, TR, RM, EA, VR, MA declare no financial conflicts of interest. MI declares consultancy for US Sanofi, Bristol Myers Squibb and ADC therapeutics; HM declares consultancy or advisory board member: Bristol Myers Squibb, CRISPR Therapeutics, Incyte, Jazz Pharmaceuticals, Senti Bioscience, Autolus, Kite\/Gilead, Sobi; medical monitor for Bone Marrow Transplant Clinical Trial Network; TN declares clinical trial research support to the institution from Novartis and Karyopharm; RP declares serving on the advisory board for Sanofi Aventis and Astra Zeneca, has received honoraria from Sanofi Aventis, Astra Zeneca and Beigene, and has received research funding from Bristol Myers Squibb Foundation, Beigene, Cullinan Therapeutics, and GlaxoSmithKline; MAK-D declares research\/grant from Bristol Myers Squibb, Novartis, and Pharmacyclics and lecture\/honoraria from Kite Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The study selection process was summarized using the PRISMA flow diagram and methodology for conduct of systematic reviews followed the Cochrane Collaboration Handbook.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}